Abstract:Background: Inflammation and angiogenesis play prominent roles in inflammatory bowel disease.Thalidomide, as an inhibitor of inflammation and angiogenesis, is a new potent therapy option for refractory Crohn's disease (CD).Objective: To evaluate the long-term clinical efficacy and safety of thalidomide therapy in pediatric CD patients who failed conventional medications or had tuberculosis; and investigate the effect of oral thalidomide therapy on angiogenesis in pediatric CD patients.Methods: A total of 17 patients (9 boys and 8 girls) aged 11.8 ± 5.2 years with refractory CD diagnosed at the mean age of 10.2 ± 4.3 years were included in this study.Patients were administered thalidomide (2 mg/kg/d) orally at baseline.The clinical activity of disease was assessed with the Pediatric Crohn's Disease Activity Index (PCDAI) at baseline and at 1, 3, 6, 12 months.Weight-for-age Z score, laboratory evaluations and reduction in corticosteroid requirement were also used to assess clinical response.Adverse effects were recorded at each visit.In addition, colonoscopy examination after treatment was performed in 10 patients during this study.Vascular endothelial growth factor (VEGF) and CD31 for microvessel density were measured by immunohistochemistry in the pre-treatment, post-treatment and control groups.Intestinal mucosal VEGF protein levels were also evaluated with western blot.Results: All 15 patients completed 12 months follow-up.Mean PCDAI was 41.0±11.9 at baseline, the values at 1, 3, 6 and 12 months decreased to 15.2±9.6,5.3±5.0,3±3.4 and 2.3±2.6,respectively.Eleven of 12 patients who required corticosteroids for management were off the drug at 12 months.The mean period was 3.1±1.5 months.ESR, CRP and PLT levels decreased after thalidomide treatment, and there was an increase in hemoglobin level.Furthermore, a significant increase in weight-for-age Z score was observed 12 months after administration of thalidomide.Three patients experienced fatigue, and 2 drowsiness during therapy.One patient presented with transient liver function abnormity.Immunohistochemical expression of VEGF and CD31 in refractory CD patients was higher than those in the control group, and the levels were significantly reduced after thalidomide therapy.The VEGF levels in intestinal mucosa were down-regulated in post-treatment group compared with pre-treatment group.Conclusion: Thalidomide long-term treatment appears to be clinically effective and well tolerated.It is a relatively safe drug in refractory Crohn's disease patients and those with tuberculosis.Mechanism of action of thalidomide therapy in CD might be associated with inhibition of angiogenesis which may be mediated by suppression of VEGF expression in the mucosa.Colonoscopy showed obvious mucosal healing in pediatric CD patients.Mucosal appearances before (A, B, C) and after (D, E, F) administration of thalidomide. S-452 AGA AbstractsMean values of the laboratory parameters-ESR(A), CRP(B), PLT (C), Hb (D)-at baseline and 1, 3, 6, 12 months(m).Results showed a significant improvement in blood tests.ESR=erythrocyte sedimentation rate; CRP=C-reactive protein; Hb=hemoglobin; PLT=platelet count.

Clinical observation of thalidomide in treating different types of cutaneous lesions of lupus erythematosus

Thalidomide treatment in cutaneous lesions of systemic lupus erythematosus: a multicenter study in China

Observation on the Effect of Thalidomide for the Treatment of Crohn's Disease

Topical thalidomide having good effect on refractory chronic discoid lupus erythematosus: a case report]

The Efficacy and Safety of Thalidomide in the Treatment of Refractory Crohn's Disease in Adults: a Double-Center, Double-Blind, Randomized–controlled Trial

Preliminary Efficacy of Thalidomide in Refractory Crohn's Disease Treatment

Thalidomide in refractory Crohn′s disease: long-term efficacy and safety

Clinical Efficacy of Low Dose Thalidomide in the Treatment of Patients with Idiopathic Myelofibrosis

Thalidomide is a Therapeutic Agent That is Effective in Inducing and Maintaining Endoscopic Remission in Adult CD Patients

Comparison of Efficacy and Safety Outcomes of Different Doses Schedules of Thalidomide for Treating Moderate-to-Severe Β-Thalassemia Patients

Thalidomide in Combination with Fludarabine,Mitoxantrone,Dexamethasone in the Treatment of Patients with Chronic Lymphoprolifcrative Disorders: Report of Six Cases

An Observation of Combined Therapy with Thalidomide in High Risk MDS and Myelofibrosis

Thalidomide Improves Clinical Symptoms of Primary Cutaneous Amyloidosis: Report of Familiar and Sporadic Cases

Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus

Successful Treatment with Thalidomide for Pemphigus Vulgaris

Observation on the Changes of Serum TNF-α Levels in Patients with Multiple Myeloma Treated with Thalidomide

A randomized double-blind, positive-control trial of topical thalidomide in erosive oral lichen planus.

Clinical Analysis of Thalidomide Companied Dexamethasone in the Treatment of Patients with Initial Multiple Myeloma

Clinical Study on Thalidomide Alone or Combined with Dexamethasone in the Treatment of Relapsed and Refractory Multiple Myeloma

Efficacy, Safety, and Potential Biomarkers of Thalidomide Plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma

Clinical Efficacy and Mechanism of Action of Thalidomide in Pediatric Patients With Refractory Crohn's Disease